Lexaria Bioscience Corp.
LEXX · NASDAQ
11/30/2025 | 8/31/2025 | 5/31/2025 | 2/28/2025 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | 0.05 | -0.03 | 0.38 |
| FCF Yield | -4.34% | -15.35% | -19.20% | -5.82% |
| EV / EBITDA | -11.74 | -5.82 | -3.81 | -7.06 |
| Quality | ||||
| ROIC | -33.79% | -99.13% | -70.99% | -40.10% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.62 | 0.98 | 0.95 | 0.55 |
| Growth | ||||
| Revenue 3-Year CAGR | 23.11% | 46.13% | 26.18% | 16.97% |
| Free Cash Flow Growth | 62.76% | 26.27% | -139.27% | 45.05% |
| Safety | ||||
| Net Debt / EBITDA | 2.66 | 0.63 | 1.20 | 2.31 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4,375.79 | 190.53 | 185.24 | 171.29 |